A bioequivalence study with a combination tablet formulation of rosiglitazone (RSG) and glimepiride (GLIM) (4mg/2mg) compared to concomitant dosing of RSG 4mg tablet and GLIM 1mg commercial tablet x 2 (4mg+2mg) in Japanese healthy male subjects

Trial Profile

A bioequivalence study with a combination tablet formulation of rosiglitazone (RSG) and glimepiride (GLIM) (4mg/2mg) compared to concomitant dosing of RSG 4mg tablet and GLIM 1mg commercial tablet x 2 (4mg+2mg) in Japanese healthy male subjects

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2015

At a glance

  • Drugs Glimepiride; Rosiglitazone; Rosiglitazone/glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Feb 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov
    • 12 Jun 2008 Status changed from initiated to discontinued as reported by ClinicalTrials.gov.
    • 08 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top